Skip to content
Should EGFR TKI Therapy be Continued Beyond Progression? episode artwork

Oct 26, 2015 2 min

Should EGFR TKI Therapy be Continued Beyond Progression?

from GRACEcast Hosted by cancerGRACE Meetings

Dr. Greg Riely, medical oncologist from MSKCC, discusses the controversial question of whether patients should continue on an oral EGFR tyrosine kinase inhibitor after progression.

Episode details come from the podcast's RSS feed.

Embed this episode

Ready to play

Should EGFR TKI Therapy be Continued Beyond Progression?

0:00 2:52

No transcript yet.

Requests help us decide what to transcribe next.

Frequently asked questions

How long is this episode of GRACEcast?

This episode is 2 minutes long.

When was this GRACEcast episode published?

This episode was published on October 26, 2015.

Can I download this GRACEcast episode?

Yes. Use the download control on the episode player to save the publisher-provided media file.